• Lenalidomide (CC-5013) in Myeloma Assays

  2026-08-26

  Use Lenalidomide (CC-5013) to connect antimyeloma activity with immune restoration, angiogenesis control, and innate immune reprogramming. This workflow-oriented guide shows how to build combination assays around DOT1L inhibition while avoiding common dosing, solubility, and interpretation errors.

• Baicalin Reopens Adult Visual Plasticity in Amblyopia

  2026-08-26

  A 2026 NeuroImage study shows that Baicalin can restore ocular dominance plasticity and visual acuity in adult mice with amblyopia when paired with reverse suturing. The work links this recovery to reduced GABAergic inhibition and perineuronal nets in the primary visual cortex, providing a mechanistic basis for pharmacologically reopening adult plasticity.

• Neuromedin S (rat): Practical GPCR Assay Guide

  2026-08-25

  Neuromedin S (rat), SKU B5466, is a defined rat peptide agonist for controlled neuromedin U receptor signaling and GPCR/G protein signaling workflows, with specified dissolution and storage conditions. It is intended for research assay development—not diagnostic, therapeutic, or unsupported cross-species use—and the absence of directly matched paper evidence means concentration and timing must be established for each assay.

• STING agonist-1 Assay Workflows

  2026-08-25

  Build reproducible STING activation assays with STING agonist-1, from DMSO preparation and dose–time scouting to IRF4-focused B-cell and tumor-immunity readouts. The workflow translates recent ESCC findings into practical controls for separating direct pathway activation from CD40-linked, paracrine effects.

• Acetoacetic Acid Sodium Salt: Assay Workflow Guide

  2026-08-24

  Build reproducible ketone-body exposure experiments with a defined, water-soluble sodium salt rather than relying on poorly controlled metabolic conditions. This guide covers preparation, dose design, LC-MS-aware validation, and troubleshooting for energy metabolism research and diabetes models.

• MMP-2-Responsive Liposome for Breast Cancer Immunotherapy

  2026-08-24

  The reference study develops NLG919@Lip-pep1, a cascade-targeted liposome that sequentially delivers the PD-1 pathway blockade peptide AUNP-12 and the IDO inhibitor NLG919. Its MMP-2-triggered exposure of a secondary targeting module is designed to remodel the immunosuppressive breast cancer microenvironment and improve antitumor immune activity.

• STING Agonist-1: From Pathway to Translation

  2026-08-23

  A translational framework for using STING agonist-1 to connect innate immune signaling with B cell activation, tertiary lymphoid structures, and cancer immunotherapy research.

• Hydroxychloroquine Sulfate: Workflow Guide

  2026-08-22

  Hydroxychloroquine Sulfate (SKU B4874) supports aqueous cellular and animal-model workflows investigating autophagy pathway modulation and TLR7/9-dependent immune signaling. It is suited to autoimmune disease research, including systemic lupus erythematosus and rheumatoid arthritis models, but is not appropriate for protocols requiring DMSO or ethanol solubility or long-term storage of prepared solutions.

• Nonselective β-Blockers Impair HCT Engraftment

  2026-08-22

  The reference study shows that nonselective β-adrenergic blockade, exemplified by carvedilol, can delay hematopoietic regeneration after allogeneic hematopoietic cell transplantation (HCT), whereas β1-selective blockade did not produce the same effect. By combining mouse transplantation models with human outcome analyses, the work identifies β2/β3-adrenergic signaling as a clinically relevant component of post-transplant marrow recovery.

• Inhaled RNA Rewires Collagen for Lung Cancer Immunotherapy

  2026-08-21

  The reference study develops an inhalable lipid nanoparticle that co-delivers anti-DDR1 scFv mRNA and PD-L1 siRNA to remodel the physical and immunosuppressive barriers of lung tumors. In orthotopic and metastatic mouse models, this dual mechanism promoted collagen rearrangement, improved immune access, suppressed tumor growth, and extended survival.

• Mutational Drivers and Drug Resistance in Myeloma Cells

  2026-08-20

  Vikova et al. established a broad exome-based map of mutations across human multiple myeloma cell lines, identifying both established drivers and previously underappreciated genes linked to oncogenic pathways and drug response. The study provides a practical framework for selecting genetically appropriate models in multiple myeloma and hematological malignancy research while clarifying the limits of cell-line-based conclusions.

• Imatinib Hydrochloride: A Phosphatase-Aware View

  2026-08-20

  Imatinib hydrochloride is a versatile ATP-site kinase probe for chronic myelogenous leukemia and gastrointestinal stromal tumor research. This article adds a phosphatase-aware framework for separating direct kinase inhibition, activation-loop regulation, and cellular phenotype.

• Epacadostat: From IDO1 Potency to Immune Context

  2026-08-19

  Epacadostat (INCB024360) is an oral IDO1 inhibitor that connects precise enzyme inhibition with complex immune-metabolic assay design. This guide explains how to interpret its potency across recombinant, cellular, and whole-blood systems without overextending the evidence.

• Thermal-Protective Hydrogel for Curative Tumor Ablation

  2026-08-19

  The reference study introduces an injectable MR@CaP@HA hydrogel that combines local thermal insulation with pH- and glutathione-responsive delivery of mitoxantrone and Resiquimod (R-848) during radiofrequency ablation. By protecting adjacent tissue while promoting immunogenic cell death, dendritic-cell maturation, and M1 macrophage polarization, the platform improved residual-tumor control and achieved complete tumor eradication in a subset of treated animals.

• Dual-Action Inhibitors and p38α Dephosphorylation

  2026-08-18

  The referenced preprint shows that selected kinase inhibitors can do more than block p38α catalytic activity: they can also accelerate WIP1-mediated dephosphorylation by reshaping the kinase activation loop. This structural mechanism suggests a route toward more selective p38 MAPK signaling pathway modulation, while requiring further cellular validation.

8371 records 1/559 page Next 12345 下5页 Last page